SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCSeptember 16, 2026

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Trastuzumab deruxtecan given as first-line treatment extended median progression-free survival by six months over the current standard of care in HER2-mutant advanced non-squamous non-small cell lung cancer, on results from the Phase III DESTINY-Lung04 trial presented during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer in Seoul (abstract PL03.08).
Share
First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

In brief

  • First-line trastuzumab deruxtecan reduced the risk of progression or death by 37.0% against platinum-pemetrexed chemotherapy with pembrolizumab in HER2-mutant advanced non-squamous NSCLC (hazard ratio 0.63; 95% CI 0.50–0.79; p<0.0001).
  • Median progression-free survival by blinded independent central review was 14.3 months against 8.3 months, and the objective response rate was 70.0% against 44.5%, with median duration of response 13.4 against 9.7 months.
  • Overall survival data were 46.9% mature, no formal hypothesis testing was performed, and no overall survival benefit was observed. AstraZeneca says varied and imbalanced subsequent therapy may limit the interpretation of that result, with HER2-directed therapy given afterwards to 48.0% of the chemotherapy arm against 23.3% of the trastuzumab deruxtecan arm.
  • Interstitial lung disease or pneumonitis was adjudicated in 20.8% of patients given trastuzumab deruxtecan, including five Grade 3, one Grade 4 and four Grade 5 events.
  • Grade 3 or higher treatment-related adverse events were 34.1% against 33.6%, on a median treatment exposure of 12.3 months against 7.1 months.

Study at a glance

  • Cohort: 454 patients, randomised 1:1 at sites in Asia, Europe and North America
  • Population: unresectable, locally advanced or metastatic non-squamous NSCLC carrying a HER2 exon 19 or exon 20 mutation
  • Treatment: trastuzumab deruxtecan 5.4 mg/kg against platinum-pemetrexed doublet chemotherapy with pembrolizumab
  • Primary endpoint: progression-free survival by blinded independent central review
  • Progression-free survival: median 14.3 against 8.3 months; HR 0.63 (95% CI 0.50–0.79; p<0.0001)
  • Response: objective response rate 70.0% against 44.5%; median duration of response 13.4 against 9.7 months
  • Overall survival: 46.9% mature, no formal hypothesis testing, no observed benefit
  • What was not reported: median overall survival in either arm, a hazard ratio for overall survival, and any result for the secondary endpoint PFS2
  • Safety: Grade 3 or higher treatment-related adverse events 34.1% against 33.6%; adjudicated interstitial lung disease or pneumonitis in 20.8% of the trastuzumab deruxtecan arm

A hazard ratio of 0.63, and six months of additional progression-free survival

On the primary endpoint, trastuzumab deruxtecan monotherapy reduced the risk of disease progression or death by 37.0% against pembrolizumab with chemotherapy, on a hazard ratio of 0.63 (95% CI 0.50–0.79; p<0.0001). Median progression-free survival was 14.3 months against 8.3 months, assessed by blinded independent central review.

DESTINY-Lung04 is a global, randomised, open-label trial of 454 patients with unresectable, locally advanced or metastatic non-squamous NSCLC carrying a HER2 exon 19 or exon 20 mutation, enrolled at sites in Asia, Europe and North America and randomised 1:1. The comparator is the current first-line standard of care in this population, a platinum-pemetrexed doublet given with pembrolizumab. HER2 mutations have been reported in approximately 2 to 4% of patients with non-squamous NSCLC, occurring predominantly in younger women and in people with no smoking history, and have been associated with an increased incidence of brain metastases.

Responses in 70.0% of patients, lasting a median of 13.4 months

The objective response rate was 70.0% with trastuzumab deruxtecan against 44.5% with pembrolizumab and chemotherapy. Median duration of response was 13.4 months against 9.7 months. Response rate and duration of response are secondary endpoints, assessed by both blinded independent central review and investigators; the release reports one set of figures without saying which assessment they come from.

AstraZeneca reported a favourable progression-free survival trend across key subgroups, and listed brain metastases, liver metastases, smoking status, HER2 mutation status by exon, and de novo or recurrent disease as prespecified stratification factors. The trial description in the same release says randomisation was stratified by smoking history and by the presence or history of brain metastasis. No subgroup hazard ratios were released.

No overall survival benefit at 46.9% maturity, with subsequent treatment imbalanced

Overall survival data were 46.9% mature at the time of this analysis and no formal hypothesis testing was performed. No overall survival benefit was observed. AstraZeneca states that varied and imbalanced patterns of subsequent therapy between the arms may limit the interpretation of that result.

The imbalances given are that HER2-directed therapies were used afterwards in 48.0% of patients in the pembrolizumab and chemotherapy arm against 23.3% in the trastuzumab deruxtecan arm, and that subsequent immunotherapy with chemotherapy was used in 23.8% of the trastuzumab deruxtecan arm. No median overall survival, hazard ratio or confidence interval was released for either arm, so the overall survival result is not on the record in numbers.

“HER2-mutant non-small cell lung cancer is an aggressive disease with limited responses to current first-line standard of care, and many patients experience disease progression within a year of starting treatment. With seventy per cent of patients responding and a median progression-free survival of 14.3 months, trastuzumab deruxtecan has the potential to become an important new first-line treatment option for these patients.”Julia Rotow, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute and lead investigator of the trial

Interstitial lung disease adjudicated in 20.8%, including four Grade 5 events

Interstitial lung disease or pneumonitis occurred in 20.8% of patients treated with trastuzumab deruxtecan, as determined by an independent adjudication committee. Most events were low grade: Grade 1 in seven patients (3.1%) and Grade 2 in 30 patients (13.3%).

The remainder were five Grade 3 events (2.2%), one Grade 4 (0.4%) and four Grade 5 (1.8%). The four Grade 5 events were recorded in a trial that reported a six-month gain in median progression-free survival and no overall survival benefit at this analysis. No corresponding adjudicated figure for the comparator arm was released.

Grade 3 or higher treatment-related events at 34.1% against 33.6%, on longer exposure

AstraZeneca reported that the safety profile of trastuzumab deruxtecan in DESTINY-Lung04 was generally consistent with its known profile, with no new safety concerns identified. Grade 3 or higher treatment-related adverse events were comparable between the arms, at 34.1% with trastuzumab deruxtecan and 33.6% with pembrolizumab and chemotherapy.

That comparison is made on unequal time on treatment: median exposure was 12.3 months in the trastuzumab deruxtecan arm against 7.1 months in the comparator arm. The most common Grade 3 or higher adverse event reported in 5% or more of patients in both arms was neutropenia, at 11.1% with trastuzumab deruxtecan and 14.1% with pembrolizumab and chemotherapy. Trastuzumab deruxtecan is currently approved in more than 80 countries for patients with unresectable or metastatic NSCLC carrying activating HER2 mutations who have already received a prior systemic therapy.

Sources

  1. AstraZeneca. Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial (2026-09-14). astrazeneca.com
  2. Daiichi Sankyo. Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial (2026-09-14). daiichisankyo.com

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

N. Reguart
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
Girard ADCs
Oct 05 2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu